CEACAM5 and neoplasm: This CD3-BsAb was tested in patients with advanced CEA-positive carcinomas and displayed signs of anti-tumor effects (5% PR, 11% SD) with a manageable toxicity profile, which was most likely associated with tumor lesion inflammation [72].